Michael H. Davidson, MD, FACC, FACP, FNLA is Clinical Professor and Director of Preventive Cardiology at the University of Chicago. He also serves as Consulting CMO for Omthera Pharmaceuticals. Dr. Davidson earned his medical degree from The Ohio State University College of Medicine in Columbus. He then completed his residency and fellowship in cardiology at Rush University Medical Center in Chicago.
An active researcher, Dr. Davidson’s clinical research background encompasses both pharmaceutical and nutritional clinical trials. His extensive research on statins, novel lipid-lowering drugs, and nonpharmacologic risk factor reduction has established him as a key opinion leader in this area. A prolific author and lecturer on lipid disorders, nutrition, and atherosclerosis, Dr. Davidson has coordinated more than 1,000 clinical trials in areas of preventive cardiology and published more than 250 articles for leading medical journals and has written 3 books on lipidology.
Dr. Davidson is board-certified in internal medicine, cardiology, and clinical lipidology. He is a Fellow of the American College of Cardiology and the American College of Chest Physicians. In addition, he is President (2010-2011) of the National Lipid Association. He was named in The Best Doctors in America for the past 10 years and was named Father of the Year by the American Diabetes Association, 2010.
Peter P. Toth, MD, PhD received his bachelor’s degree in biochemistry from Princeton University and a PhD in biochemistry from Michigan State University. He graduated from Wayne State University School of Medicine and completed residency training in Family Medicine at the University of Iowa Hospitals and Clinics.
Dr. Toth is a Diplomate of the American Board of Family Practice and the American Board of Clinical Lipidology. He is a member of the American College of Cardiology Foundation Council on Cardiovascular Disease Prevention and the American Heart Association’s Council on Lipoproteins, Lipid Metabolism, and Thrombosis.
Dr. Toth has authored or co-authored more than 220 publications in medical and scientific journals and textbooks. He is Editor-in-Chief of the Year in Lipid Disorders (Atlas Publishing, Oxford, UK) and an Associate Editor for the Year Book of Endocrinology. He is co-editor with Antonio Gotto on the textbook, Comprehensive Management of High Risk Cardiovascular Patients (Taylor and Francis, New York); with Michael Davidson on Therapeutic Lipidology (Humana, Philadelphia); with Dominic Sica on Current Controversies in Dyslipidemia Management (Atlas Publishing, Oxford); with Kevin Maki on Practical Lipid Management (Wiley-Blackstone, London); with Christopher Cannon on Comprehensive Cardiovascular Care in the Primary Care Setting (Springer Humana, Philadelphia); and with Domenic Sica on Clinical Challenges in Hypertension volumes I and II (Clinical Publishing, Oxford, UK). He has lectured on many topics in cardiovascular medicine throughout the US.
William E. Boden, MD, FACC, FAHA is Professor of Medicine and Preventive Medicine at the State University of New York at Buffalo Schools of Medicine and Public Health. He is Director of Cardiovascular Services at Kaleida Health System in Western New York and Chief of Cardiology at Buffalo General and Millard Fillmore Hospitals in Buffalo. He received his medical doctorate from State University of New York, Upstate Medical Center, Syracuse, NY, in 1974. Dr. Boden performed his internal medicine training at Boston University Medical Center (1974-1977) and went on to complete his fellowship training in cardiology at Tufts University School of Medicine in Boston, MA. He is board-certified in both internal medicine and in the subspecialty of cardiovascular diseases. Since 1979, Dr. Boden has held university appointments at Brown University, Wayne State University, Tufts New England Medical Center, Boston University, the University of Connecticut, and currently at the State University of New York in Buffalo.
Dr. Boden’s principal research interests include studies in post-myocardial infarction secondary prevention, acute coronary syndromes and unstable angina, congestive heart failure, and dyslipidemia in post-myocardial infarction (MI) and coronary artery disease (CAD). He has worked extensively in the clinical trials arena of non-Q-wave MI and in assessing the role of calcium antagonists in patients with ischemic heart disease, notably in non-Q-wave MI secondary prevention. Dr. Boden has been involved in clinical research investigator activities as the project director, study chairman, and co-chairman for multicenter clinical trials, and served as a principal investigator, steering committee member, and consultant for numerous clinical research grant activities funded by the Department of Veterans Affairs, the NIH, and industry. He was the study chairman and study co-chairman for the VANQWISH and INTERCEPT trials, respectively. Currently he is the study co-chairman and lead investigator in the COURAGE trial (the largest randomized trial comparison of percutaneous coronary intervention [PCI] vs optimal medical therapy in stable CAD patients), and is the study co-chairman of the NIH-funded AIM-HIGH trial evaluating the long-term role of combination dyslipidemic therapy (niacin and statin vs statin) in CAD patients with low HDL-cholesterol.
Dr. Boden has lectured widely and written more than 350 peer-reviewed publications, original articles, books, chapters, and abstracts. He has been selected as one of the Best Doctors in America continuously since 2003. He is a member of several professional cardiology organizations and editorial boards, including the American Journal of Cardiology, Journal of the American College of Cardiology, Clinical Cardiology, Journal of Cardiovascular Pharmacology and Therapeutics, and World Journal of Cardiology. Dr. Boden also serves as an editorial reviewer for New England Journal of Medicine, Annals of Internal Medicine, Circulation, Journal of the American Medical Association, American Heart Journal, and Archives of Internal Medicine.
Michael Miller, MD, FACC, FAHA serves as Professor of Medicine in the Division of Cardiology and Professor of Epidemiology and Preventive Medicine at the University of Maryland School of Medicine. In addition, he is Director of the Center for Preventive Cardiology at the University of Maryland Medical System and Staff Physician at the Veterans Affairs Medical Center in Baltimore. His major research interests are disorders of lipid and lipoprotein metabolism, molecular studies of HDL cholesterol, triglycerides and the postprandial response to dietary fat, nontraditional coronary risk factors, and clinical trials to reduce atherosclerosis. Dr. Miller has participated in landmark clinical trials including AVERT, MIRACL, PROVE-IT, TNT and COURAGE.
He is certified by the National Board of Medical Examiners and the American Board of Internal Medicine, including certifications in internal medicine and clinical lipidology and recertification in cardiovascular disease. Dr. Miller is a Fellow of the American College of Cardiology and the American Heart Association Council on Arteriosclerosis. He is also an active member of the American Heart Association Council on Epidemiology.
Dr. Miller has authored more than 250 original articles, book chapters, and other publications. Original research articles have appeared in the BMJ, Circulation, JACC, JAMA, NEJM, PNAS and Science. He is the co-author of The Practice of Coronary Disease Prevention, published by Williams and Wilkins (1996) and the AMA Guide to Preventing and Treating Heart Disease (2008). Dr. Miller has served on the program faculty for the American College of Cardiology Self-Assessment Program (ACCSAP) and Complex Lipid Management Self-Assessment Program that involves preparation for certification in Cardiology and Clinical Lipidology, respectively, and most recently as Chair for the AHA Scientific Statement: Triglycerides and Cardiovascular Disease. Currently, he is an Associate Editor for the journal BMC Public Health, and a member of several other editorial boards.
Dr. Miller is Past President of the American Society of Preventive Cardiology. His research has been supported by the National Institutes of Health, American Heart Association, and Veteran's Affairs Administration. He received a bachelor’s degree from Rutgers College and his medical doctorate from the University of Medicine and Dentistry of New Jersey. Following a medical residency at the University of Cincinnati Hospital, he completed two fellowships at Johns Hopkins, one in lipoprotein metabolism and the second in cardiovascular disease.